PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients

Background: We aimed to demonstrate the function of premelanosome protein (PMEL) as a biomarker to predict the effectiveness of mammalian target of rapamycin complex 1 (mTORC1) inhibitor treatment in renal angiomyolipomas (RAMLs) in tuberous sclerosis complex (TSC) patients. Methods: 95 whole blood...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Dongxu Qiu, Zhan Wang, Xu Wang, Yutao Wang, Wenda Wang, Yushi Zhang
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-08-01
Serija:	Heliyon
Teme:	PMEL Tuberous sclerosis complex Renal angiomyolipoma Treatment efficacy prediction
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2405844024109681
Oznake:	Označite Brez oznak, prvi označite!